Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Sensors (Basel, Switzerland)
|
April 26, 2025
Enhancing Bottleneck Concept Learning in Image Classification
Xingfu Cheng, Zhaofeng Niu, Zhouqiang Jiang, et al.
Sensors (Basel, Switzerland)
|
February 26, 2022
DFusion: Denoised TSDF Fusion of Multiple Depth Maps with Sensor Pose Noises
Zhaofeng Niu, Yuichiro Fujimoto, Masayuki Kanbara, et al.
Oncology Letters
|
January 19, 2019
miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression
Xiaoke Hou, Zhaofeng Niu, Leilei Liu, et al.
International Journal of Cancer
|
August 6, 2023
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
Yiqun Li, Zhongsheng Tong, Xinhong Wu, et al.
Nature Communications
|
January 2, 2025
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study
Ying Fan, Qingyuan Zhang, Min Yan, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
June 2, 2025
Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer
Lina Zhang, Cuizhi Geng, Mingxia Wang, et al.
BMC Cancer
|
May 27, 2025
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
Benlong Yang, Zhengkui Sun, Quchang Ouyang, et al.
British Journal of Cancer
|
June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Wenjia Zuo, Zhonghua Wang, Jun Qian, et al.
JAMA Oncology
|
March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Sensors (Basel, Switzerland)
|
April 26, 2025
Enhancing Bottleneck Concept Learning in Image Classification
Xingfu Cheng, Zhaofeng Niu, Zhouqiang Jiang, et al.
Sensors (Basel, Switzerland)
|
February 26, 2022
DFusion: Denoised TSDF Fusion of Multiple Depth Maps with Sensor Pose Noises
Zhaofeng Niu, Yuichiro Fujimoto, Masayuki Kanbara, et al.
Oncology Letters
|
January 19, 2019
miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression
Xiaoke Hou, Zhaofeng Niu, Leilei Liu, et al.
International Journal of Cancer
|
August 6, 2023
Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study
Yiqun Li, Zhongsheng Tong, Xinhong Wu, et al.
Nature Communications
|
January 2, 2025
Intravenous liposomal irinotecan in metastatic triple-negative breast cancer after ≥ 2 prior lines of chemotherapy: a phase Ib study
Ying Fan, Qingyuan Zhang, Min Yan, et al.
International Journal of Clinical Pharmacology and Therapeutics
|
June 2, 2025
Bioequivalence of two doxorubicin liposome formulations (LY01612 and Caelyx) using free and encapsulated doxorubicin concentrations in Chinese patients with advanced breast cancer
Lina Zhang, Cuizhi Geng, Mingxia Wang, et al.
BMC Cancer
|
May 27, 2025
Safety and quality of life of CDK4/6 inhibitors therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: a multicenter cross-sectional survey in China
Benlong Yang, Zhengkui Sun, Quchang Ouyang, et al.
British Journal of Cancer
|
June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trial
Wenjia Zuo, Zhonghua Wang, Jun Qian, et al.
JAMA Oncology
|
March 19, 2026
Bireociclib Plus Fulvestrant in Advanced Breast Cancer After Endocrine Progression: The BRIGHT-2 Phase 3 Randomized Clinical Trial
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Nature Communications
|
April 9, 2025
Bireociclib plus fulvestrant for HR+/HER2- advanced female breast cancer progressed on or after endocrine therapy: phase 3 BRIGHT-2 study interim analysis
Jiayu Wang, Qingyuan Zhang, Huiping Li, et al.
Page
of 2